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Multivariate Analysis of Clinical Predictors of Overall Survival (n¼92)
Characteristic HR (95% CI) P-Value
KPS <90 2.08 (1.10-3.92) 0.023
HCT-CI 4+ 2.77 (1.44-5.32) 0.002
Not in CR 1.16 (0.59-2.32) 0.664
Age >65 1.32 (0.70-2.51) 0.393
Plt Engraftment >15 Days 2.48 (1.21-5.08) 0.013
ANC Engraftnent >14 Days 1.58 (0.84-3.00) 0.156
+ aGVHD 4.31 (1.80-10.33) 0.001
+ cGVHD 1.24 (0.53-2.95) 0.618
Risk Score: High/Very High 1.40 (0.67-2.90) 0.371
*All variables were normalized to HR¼1
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Celiac Disease Transmitted By Unrelated Cord Blood Stem
Cell Transplantation (CBST)
Abdullah Baothman. King Saud University for Heatlth Science,
Jeddah, Saudi Arabia, Oncology, King Abdulaziz Medical Center,
Jeddah, Saudi Arabia
Background: Celiac disease is due to intolerance to certain
cereal proteins leading to immune-mediated small bowel
villous atrophy and malabsorption. Speciﬁcally, the gliadin
component of wheat, and the prolamin component of rye
and barley are implicated in causing disease. BMT and CBST
have been known to transmit immune associated diseases
such as diabetes mellitus immune thrombocytopenic pur-
pura from an affected donor to transplant recipient.
Methods & Results: We observed the occurrence of Celiac
disease in a patient a year following cord blood stem cell
transplantation (CBST) for acute myelogenous leukemia
(AML- FAB M2) in complete second remission (CR-2). The
patient had no history of celiac disease prior to CBST nor any
family member. The cord donor was HLA-identical unrelated
male donor with HLA types: A3, B7 (w6), DR (B1), DR (B5).
The family history of the donor was unavailable for celiac
disease. The CBST was complicated by grade 2 skin Graft
versus Host Disease (GVHD), which responded to steroid
therapy. A year post transplantation she developed persis-
tent mucous diarrhea with tinge of blood associated with
abdominal cramps. Investigations for infectious causes such
as CMV enteritis were negative and colonsocopy did not
reveal any evidence of GVHD. Gastrointestinal symptoms
persisted and did not respond to steroid and prograf therapy.
Subsequent duodenal and jejunal biopsy revealed subtotal
villous atrophy with cryptic hyperplasia suggestive of celiac
disease. Antigliadin IgA and IgG, reticulin IgA and Endomy-
sial IgA andibodies were elevated. A diagnosis of post-CBST
coeliac disease was made. She responded well to gluten-free
diet and became symptom-free.
Discussion & Conclusion: A literature review identiﬁes only
from donor to recipient one previous example of trans-
mission of celiac disease following HSCT. This case could be
the second case of celiac disease following transplantation
and the ﬁrst one post CBST. An association of celiac disease
with some HLA types, including DQA1.0501, and DQB1.0201,
in conjunction with the haplotypes A30, B18, DR3, DRw52,
and DQ2 was recently noted. The donor of this case exhibit
HLA DQ A1.0501 and DQ B1.0201 alleles. The ﬁndings sug-
gest transfer of celiac disease by cord stem cells and conﬁrm
the immune nature of the disease. In addition the pro-
pensity to develop T-cell non-Hodgkin lymphoma and
transmission of celiac disease by CBST support T cell concept
in celiac disease. Autoimmune enteropathy should be
considered in patient with persistent diarrhea post hemo-
poietic stem cell transplant.
329
Non-Myeloablative (NMA) Allogeneic Hematopoietic
Stem Cell Transplant for the Treatment of Patients with
Hematologic Malignancies Using Busulfan, Fludarabine
and Total Body Irradiation (Bu/Flu/TBI) Conditioining:
Results of a Phase II Trial
Jonathan E. Brammer 1, Alex Stentz 1, James Dibb 1,
Rachel Frires 1, Gabrielle Meyers 1, Peter Curtin 2,
Tibor Kovacsovics 3, Jose Leis 4, James Gajewski 1,
Richard T. Maziarz 5. 1 Center for Hematologic Malignancies,
Knight Cancer Institute, Oregon Health & Science University,
Portland, OR; 2Medicine, University of California, San Diego, LaJolla, CA; 3Hematology and Hematologic Malignancies,
University of Utah Huntsman Cancer Institute, Salt Lake City,
UT; 4Hematology Oncology/Blood and Marrow Transplant,
Mayo Clinic Arizona, Phoenix, AZ; 5 Center for Hematologic
Malignancies, Knight Cancer Institute, Oregon Health and
Science University, Portland, OR
Introduction: Non-myeloablative (NMA) allogeneic trans-
plant for the treatment of hematologic malignancies has
become the standard of care for patients unable to tolerate
myeloablative conditioning. The BuFluTBI transplant regimen
was designed with the primary goal of reducing non-relapse
mortality (NRM) while maximizing primary disease control
in older and inﬁrm patients.
Methods: Patients with high-risk hematologic malignancies
were given an outpatient conditioning regimen of busulfan
3.2 mg/kg IV on day -5, ﬂudarabine 30 mg/m2 IV on days -4,
-3, -2, and 200 cGy of total body irradiation (TBI). Sources of
hematopoietic stem cells were either from related or unre-
lated donors (at least 7/8 antigen match). GVHD prophylaxis
was given with cyclosporine and mycophenolate mofetil.
Clinical predictors of response were evaluated utilizing Cox
Proportional Hazards Model.
Results: 147 patients were enrolled from 2005-2011; 86
(59%) with myeloid disease and 61 (41%) with lymphoid
disease. Themedian agewas 64, and themedian comorbidity
index (HCT-CI) score was 3. The overall survival (OS), with 2
yearsmedian follow-up, was 60% at 1 year and 48% at 2 years,
with projected OS 37% at 5 years. Relapse rates were 29% at 1
year and 33% at 2 years, with relapse mortality of 13% at 1
year, and 20% at 2 years. NRM at 1 year was 27% and 33% at 2
years. 54% of patients developed early or late grade II-IV
acute GVHD (aGVHD), and 67% of patients developed cGVHD
within 2 years. On multivariate analysis, amongst 92 evalu-
able patients, HCT-CI score greater than 4, pre-transplant KPS
<90, delayed platelet engraftment >15 days, and aGVHD
were found to be independent predictors of poor survival as
demonstrated in the table.
Conclusions: In an inﬁrm elderly population with a high
HCT-CI, BuFluTBI is an effective regimen with favorable OS
with acceptable levels of NRM.330
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Background: Relapse after allogeneic stem cell transplant
(allo-HSCT) for acute leukaemia (AL) remains a major
